anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A macrocyclic compound having the structure of Formula (A), wherein each of R 1  and R 2  is independently (i) a 5-6 membered monocyclic aromatic ring containing 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or (ii) an 8-10 membered bicyclic aromatic ring containing 0-6 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Each R 1  and R 2  may independently be substituted by 0, 1, 2, 3, or 4 substituents. Z 1  represents a covalent bond, an atom, or a functional group comprising a grouping of atoms, wherein the grouping of atoms includes at least one heteroatom selected from the group consisting of N, O, P, and S. Also, Z 1  may represent (i) a 5-6 membered monocyclic aromatic ring containing 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or (ii) an 8-10 membered bicyclic aromatic ring containing 0-6 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Z 2  represents a covalent bond, an atom, or a functional group comprising a grouping of atoms, wherein the grouping of atoms includes at least one heteroatom selected from the group consisting of N, O, P, and S. Variable v is an integer having a value of 1 or 0. T is a carbon atom, a nitrogen atom, a sulfur atom, or an oxygen atom. L is a linking group covalently bonded to T when v has a value of 1 or L is covalently bonded to R 1  when v has a value of 0. L is covalently bonded to Z 2  when Z 2  is an atom or a functional group comprising grouping of atoms and/or L is covalently bonded to R 2  when Z 2  is a covalent bond. Each of R 3 , R 4  and R 5  may be the same as or different from each other and each is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl, and heteraralkyl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl, and heteraralkyl is optionally substituted by one or more suitable substituents.
PURPOSE: A composition containing Chrysanthemum zawadskii extract is provided to ensure conditioning effect without irritation and to prevent build up phenomenon even in long term use. CONSTITUTION: A hair conditioning composition contains Chrysanthemum zawadskii extract. The Chrysanthemum zawadskii extract is obtained using water, organic solvent or mixture thereof. The Chrysanthemum zawadskii extract is contained in 0.01-20 weight parts based on 100 weight parts of total composition. The composition is used in the form of shampoo, rinse, treatment, hair cream, conditioner, hair styling gel, hair moose, hair wax, or hair dyeing agent. A composition for scalp care contains Chrysanthemum zawadskii extract.
The underweight status among older adults in India and its association with other health risks has received little attention. Using nationally representative data from the first wave of the Longitudinal Aging Study in India (LASI, 2017-18), this study examined the underweight status among the Indian older adults and investigated its relationship with various health outcomes. The effective sample size of this study was 28,050 older adults aged 60 years or above. Multivariable logistic and linear regression models were employed to meet the objectives of the study. Underweight status was found to be negatively associated functional health, cognitive function, and grip strength. However, no significant association was observed between underweight status and depressive symptoms. Moreover, socioeconomic, demographic, and geographic factors were identified as strong determinants of underweight status among Indian older adults. India has implemented a wide range of nutrition policies that primarily focus on children, mothers, and adolescents. While these policies are important, it is equally crucial to develop interventions specifically tailored for adults and older adults.
After meeting the inclusion criteria, a total of 44 Patients in need of endodontic microsurgery with persistent symptoms after acceptable primary root canal treatment or failed retreatment with persistent symptoms/periapical lesions will be included in this study. Participants will be randomly allocated to group one; conventional periradicular surgery or group two; piezoelectric periradicular microsurgery. A preoperative digital periapical and limited view cone beam computed tomography (CBCT) radiographs will be taken for each patient. At 12-18 months recall visit a second digital periapical radiograph and limited view CBCT will be taken. All images will be evaluated on high-definition LCD display with installed ImageJ software and CBCT software, and window settings will be fixed for all cases. Radiographs will be evaluated by two calibrated dentists. The excised root tip with their surrounding tissues will be fixed immediately after harvesting for 24 hours at 4 °C by immersion in 1% glutaraldehyde and 1% formaldehyde and referred to histopathologic laboratory. Fixed specimens will be demineralized in 10% formic acid and processed. Serial sectioning with hematoxylin and eosin staining will be done to locate the areas with the most severe reactions. In addition, the Taylor modification of the Brown-Brenn staining will be used to detect the presence of bacteria.
All clinical care for the control group will be within NICU department process guidelines relevant to the gestational age of the subject and as ordered by physician and/or ARNP providers. The neutral midline head position with the aid of nesting and/or rolls with a bed elevation between 15° and 30° will be maintained throughout position changes during the first 72 hours of life, which is standard practice. Caregivers will document the NICU integrated flowsheet and the Sunrise electronic record with interventions regarding positioning, handling, skin assessment etc. per standard practice requirements.
The present invention is directed to human and nematode LAG1 nucleic acids and the polypeptides encoded and expressed thereby, including appropriate vectors and host cells. The present invention contemplates antisense RNA and DNA. This invention further provides methods for increasing the longevity and the tolerance to stress of eukaryotic cells by providing to the cell human and nematode LAG1 polypeptides. Methods for providing the cell with such LAG1 polypeptides include overexpressing the endogenous LAG1 gene, or providing the cell with an expression vector containing the appropriate LAG1 coding region. Such methods can be practiced, for example in mammalian cells, such as human cells. The present invention is also directed to pharmaceutical compositions to effect such methods.
Apoptosis repressor with caspase recruitment domain (ARC) is a highly potent and multifunctional suppressor of various types of programmed cell death (PCD) (e.g. apoptosis, necroptosis, and pyroptosis) and plays a key role in determining cell fate. Under physiological conditions, ARC is predominantly expressed in terminally differentiated cells, such as cardiomyocytes and skeletal muscle cells. Its expression and activity are tightly controlled by a complicated system consisting of transcription factor (TF), non-coding RNA (ncRNA), and post-translational modification (PTM). ARC dysregulation has been shown to be closely associated with many chronic diseases, including cardiovascular disease, cancer, diabetes, and neurodegenerative disease. However, the detailed mechanisms of ARC involved in the progression of these diseases remain unclear to a large extent. In this review, we mainly focus on the regulatory mechanisms of ARC expression and activity and its role in PCD. We also discuss the underlying mechanisms of ARC in health and disease and highlight the potential implications of ARC in the clinical treatment of patients with chronic diseases. This information may assist in developing ARC-based therapeutic strategies for patients with chronic diseases and expand researchers' understanding of ARC.
1. Technical Result Reduction of cost and simplification of technological process. 2. Essence A method provides for separation of yolk from a boiled egg, its homogenization and extracting of oil by pressing in two stages, the first of which is carried out before homogenization by preliminary heating of yolk during 8-12 minutes at temperature 100-150°C, and the second - after homogenization by preliminary heating of yolk during 3-5 min. at temperature 150-300°C. 3. Field of Application Food industry, in particular fat production, can be used in perfumery.
The invention provides a murine monoclonal antibody CD151 9B and an application thereof. The murine monoclonal antibody CD151 9B is characterized in that the murine monoclonal antibody CD151 9B is generated by a hybridoma cell with the collection number being CGMCC No.9156. According to the invention, through wide and deep researches, the murine monoclonal antibody CD151 9B targeted to a binding domain of a human CD151-integrin alpha6beta1 complex with high specificity is successfully obtained. The murine monoclonal antibody CD151 9B provided by the invention has high compatibility and can better express CD151 expression and location in a hepatoma carcinoma cell. The murine monoclonal antibody CD151 9B provided by the invention can compete a binding site of the CD151-integrin alpha6beta1 of the hepatoma carcinoma cell and inhibit the movement and invasion of the hepatoma carcinoma cell. Therefore, the murine monoclonal antibody with high affinity and specificity, provided by the invention, has better experimental and clinical application prospects.
OBJECTIVES: Acute central nervous system (CNS) infections in children can lead to neurological complications and mortality. This study aimed to identify the clinical manifestations, laboratory parameters, and cerebrospinal fluid characteristics indicative of CNS infections and define the risk factors that lead to pediatric intensive care unit (PICU) admission in the pediatric population of Şanlıurfa, a city in southeastern Turkey.
METHODS: This retrospective analysis included patients aged 1 month to 18 years who were treated for acute CNS infections in the Şanlıurfa Training and Research Hospital between January 2020 and May 2023. Clinical data were obtained from the hospital electronic medical records.
RESULTS: A total of 68 patients with acute CNS infections were included in this study. The median patient age was 3 (0.94-8.75) years. Fever was the most prevalent symptom in 92.6% of the patients. Of the total, 25% (n = 17) of the patients had an identified causative agent and 35.3% (n = 24) were admitted to the PICU. Serum C-reactive protein (CRP) levels were significantly higher in patients with bacterial meningitis than in those with viral meningitis (p = 0.007). Patients with impaired consciousness and seizure were significantly more likely to require admission to the PICU than patients without these conditions (both p < 0.001). Patients requiring PICU admission had significantly higher platelet counts (p = 0.01).
CONCLUSIONS: Impaired consciousness, seizure, and thrombocytosis on admission were important risk factors for PICU admission. Serum CRP levels can serve as an indicator of bacterial meningitis. A combination of physical findings from clinical evaluations and laboratory data is necessary to accurately diagnose bacterial CNS infections.
Hepatocellular carcinoma is a highly heterogeneous disease. Treatment strategies for advanced hepatocellular carcinoma are limited. Resulting in a poor prognosis. Phosphatidylinositol proteoglycan 3 (GPC3) is a heparan sulfate glycoprotein (HSPG) on the surface of the cell membrane. It is highly expressed in liver cancer tissues, but hardly expressed in normal liver tissues. It is an ideal target for tumor treatment. Investigators aimed to test the safety and efficacy of GPC3 CAR-T cells in patients with advanced hepatocellular carcinoma.
Older persons take on average multiple drugs. As people age, there is an apparent increase in pharmacodynamic sensitivity to different making the patient more prone to experience side effects. Alterations in body composition and concomitant changes in pharmacokinetic parameters can also result in a higher risk for adverse drug events. All these factors make the older person, notwithstanding the heterogeneity of this population, more vulnerable for the negative consequences of polypharmacy.

Polypharmacy is a cause of negative clinical outcomes but it still remains unclear which intervention or set of interventions should be used to optimize the prescription of pharmacotherapy in the elderly patient. Therefore, the investigators developed the RASP (RASP = Rationalisation of home medication by an adjusted STOPP-list in older patients; STOPP = Screening Tool of Older Persons' potentially inappropriate Prescriptions), a list as tool to reduce polypharmacy adapted to Belgian national prescribing tendencies within geriatric wards. Content and reliability of the RASP have been validated and the investigators aim to further study the impact of the systematic implementation of this RASP on geriatric wards in a prospective cluster randomized controlled trial.
This study is a randomized, hybrid type 3 effectiveness-implementation trial to support the adoption of a chronic care model (CCM)-based intervention in pediatric primary care settings by testing the impact of implementation strategies directed towards the provider care team (TEAM) or practice leadership (LEAD) level. The treatment investigators seek to deliver here is called Doctor Office Collaborative Care (DOCC), an evidence-based intervention for the management of child behavior problems and comorbid ADHD. The implementation strategies being tested to enhance DOCC uptake include TEAM coaching/consultation strategies, which will be delivered to care team providers and target provider competency to deliver DOCC, and LEAD facilitation strategies, which will be delivered to practice leaders and target organizational support of DOCC delivery. These multi-level implementation strategies have not been formally evaluated to learn about their separate and combined effects in any randomized clinical trial conducted in pediatric primary care. Such information is needed to optimize our approaches to promoting the implementation of a CCM-based intervention in pediatric practice.

The sample includes up to 24 primary care practices from a statewide network and other networks or states. After standard training in the DOCC EBP, all practices will be randomized to one of four implementation conditions: 1) No TEAM or LEAD (ongoing technical support only); 2) TEAM implementation; 3) LEAD implementation, or 4) TEAM+LEAD implementation. TEAM and LEAD implementation will be delivered via videoconference on a graded schedule. Care teams will deliver DOCC to up to 25 children (or more if requested by the practice) who meet a clinical cutoff for modest behavior problems and their caregivers. Investigators will collect practice/provider measures from enrolled practice staff (0, 6, 12, 18, 24 months) and caregivers over several timepoints (0, 3, 6, 12 months) to support all analyses evaluating implementation and treatment outcomes, mediation, and moderation. By proposing one of the first large pragmatic pediatric trials of a CCM-based evidence-based intervention to address these aims in response to RFA-MH-18-701 and the NIMH's Strategic Plan (4.2), this research will advance the implementation science knowledge needed to optimize promising strategies for promoting the delivery and scale-up of DOCC in a pediatric medical home.
PURPOSE:To obtain an easily soluble granule easy to take and enabling effective absorption of calcium component in body, by granulating a mixture composed mainly of powder of a basic calcium compound and powder of an organic acid such as malic acid. CONSTITUTION:The objective easily soluble granule can be produced by granulating a mixture composed mainly of powder of a basic calcium compound such as calcium oxide, calcium hydroxide, calcium carbonate, etc., and an organic acid (e.g. tartaric acid, citric acid, malonic acid, etc.), preferably by fluidized granulation, rolling granulation or rolling fluidized granulation process. A raw material rich in basic calcium compound is shell of oyster, scallop, wreath shell, clam, short-necked clam, corbicula, etc., which has another advantage of containing a component useful for human body e.g. various minor metals in addition to calcium. EFFECT:The bitter taste of calcium can be masked by the characteristic taste of organic acid.
A nanoparticle structure and a formation method therefor are provided. The nanoparticle structure comprises metal oxide nanoparticles. The metal oxide nanoparticles can further comprise ceria and zirconia. The nanoparticle structure can further comprise an antibody coupled to the metal oxide nanoparticles. A method for forming the nanoparticle structure comprises a step of forming metal oxide nanoparticles. The method for forming the nanoparticle structure can further comprise a step of coupling an antibody to the metal oxide nanoparticles.
The BA subject group will receive saline and then Onabotulinumtoxin. A.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
Determining the location of myocardial infarction is crucial for clinical management and therapeutic stratagem. However, existing diagnostic tools either sacrifice ease of use or are limited by their spatial resolution. Addressing this, we aim to refine myocardial infarction localization via surface potential reconstruction of the ventricles in 12-lead electrocardiograms (ECG). A notable obstacle is the ill-posed nature of such reconstructions. To overcome this, we introduce the frequency-enhanced geometric-constrained iterative network (FGIN). FGIN begins by mining the latent features from ECG data across both time and frequency domains. Subsequently, it increases the data dimensionality of ECG and captures intricate features using convolutional layers. Finally, FGIN incorporates ventricular geometry as a constraint on surface potential distribution. It allocates variable weights to distinct edges. Experimental validation of FGIN confirms its efficacy over synthetic and clinical datasets. On the synthetic dataset, FGIN outperforms seven existing reconstruction methods, attaining the highest Pearson Correlation Coefficient of 0.8624, the lowest Root Mean Square Error of 0.1548, and the highest Structural Similarity Index Measure of 0.7988. On the clinical public dataset (2007 PhysioNet/Computers in Cardiology Challenge), FGIN achieves better localization results than other approaches, according to the clinical standard 17-segment model, achieving an average Segment Overlap of 87.2%. Clinical trials on 50 patients demonstrate FGIN's effectiveness, showing an average accuracy of 91.6% and an average Segment Overlap of 88.2%.
PURPOSES: This study aims to assess the effectiveness and safety of cervical polypectomy performed via vaginoscopy in pregnant women.
METHODS: Pregnant patients diagnosed with cervical polyps were retrospectively included in Beijing Tiantan Hospital between April 2017 and April 2023. Group A underwent cervical polypectomy using a vaginoscopy technique without speculum, cervical forceps and anesthesia, while Group B received conservative management. The incidence of spontaneous abortion, preterm birth, preterm rupture of membranes (PROM), visual analog scale (VAS) scores, timing and method of delivery, and neonatal outcomes were analyzed.
RESULTS: Of 90 pregnant patients included in the study, 48 patients receiving polypectomy under vaginoscopy were included into group A while 42 patients receiving conservative treatment were assigned into group B. At baseline, group A exhibited higher rates of vaginal bleeding pre-operation, as well as larger cervical polyp dimensions compared to group B. The median interval between vaginal bleeding and polypectomy was 3.5 weeks, with the median procedure typically performed at gestational week 19 in group A. There was no significant difference in the incidence of spontaneous abortion between the two groups (4.2% vs. 4.8%, p = 1.000). However, group A showed a significantly lower frequency of preterm birth (4.2% vs. 21.4%, p = 0.030) and premature rupture of membranes (PROM) (18.8% vs. 45.2%, p = 0.025) compared to group B. No disparities were observed in the timing, mode of delivery, and neonatal outcomes between the two groups.
CONCLUSIONS: The utilization of vaginoscopy for cervical polypectomy has been shown to decrease the likelihood of preterm delivery and premature rupture of membranes in pregnant women with symptomatic cervical polyps. Therefore, performing cervical polypectomy via vaginoscopy without anesthesia provide a feasible and optimal ways in the management of this population.
Patients in this group will receive between 1-4 ml of bone marrow aspirate concentrate (BMAC) containing mesenchymal stem cells (MSCs) obtained from their iliac crest. A small incision will be made on the anterior superior iliac spine in order to withdraw the aspirate. The aspirate will be ran through a centrifuge in order to isolate the BMAC containing MSCs. The BMAC will be injected into the ACL allograft prior to implanting into the patient.
The first 227 subjects enrolled in the study belong to the "Safety Cohort". The number of subjects is required to fulfill the sample size requirement of the primary safety endpoint. The "Safety Cohort" subjects are not required to participate in the Holter study. Once the "Safety Cohort" enrollment is completed, all subsequent subjects are required to participate in the Holter study. All subjects who participate in the Holter study belong to the "Holter Cohort".
A randomized controlled trial will examine mindfulness-based relapse prevention (MBRP) program outcomes for 240 individuals who have completed treatment for opioid or alcohol use disorders. Participants will be recruited from outpatient medical clinics and substance use recovery centers. They will be assigned to an intervention group (Group 1) or waitlist control (Group 2), completing assessments at baseline, 8, and 16 weeks. Group 1 will receive the intervention in weeks 1-8 and group 2 will receive the intervention in weeks 9-16. MBRP is a group aftercare program that integrates mindfulness skills training with cognitive-behavioral relapse prevention strategies. Primary outcomes will include frequency of opioid/alcohol use, craving, withdrawal, and quality of life. Secondary outcomes include time to first opioid/alcohol use, adherence to medication-assisted treatment plans, perceived stress, posttraumatic stress symptoms, and chronic pain. We will also examine the following potential moderators of intervention outcomes: comorbid diagnoses, life events history, and MBRP intervention adherence. In addition, we will examine the following mediators of intervention outcome: mindfulness skills, emotion regulation skills, executive functioning skills, savoring, and positive and negative affect.